The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats

Journal of Receptors and Signal Transduction

Volumn 34, Issue 6, 2014, Pages 445-455

  Yang, Yang ^a   Ni, Weijian ^a   Cai, Ming ^b   Tang, Liqin ^c   Wei, Wei ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Berberine; Course of disease; Diabetic nephropathy; EP4

Indexed keywords

BERBERINE; CYCLIC AMP; ENALAPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; METFORMIN; PROSTAGLANDIN E RECEPTOR 4; SIMVASTATIN; PTGER4 PROTEIN, MOUSE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; GLUCOSE INTAKE; KIDNEY CORTEX; KIDNEY HYPERTROPHY; KIDNEY TUBULE; LIPID DIET; LUNG INTERSTITIUM; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

RATTUS;

ANIMALS; BERBERINE; CYCLIC AMP; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; MALE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SIGNAL TRANSDUCTION; STREPTOZOCIN; TREATMENT OUTCOME;

EID: 84911896162     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2014.917324     Document Type: Article

References (38)

1. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006;6: 479-83.
2. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30-3.
3. Kanwar YS, Akagi S, Sun L, et al. Cell biology of diabetic kidney disease. Nephron Exp Nephrol 2005;101:e100-10.
4. Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59: 247-58.
5. Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278: 12151-6.
6. Jensen BL, Mann B, Skott O, et al. Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. Kidney Int 1999;56:528-37.
7. Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 2006;290:F1534-42.
8. Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 2010;21: 1678-90.
9. Nakagawa N, Yuhki K, Kawabe J, et al. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 2012;82: 158-71.
10. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab Clin Exp 2008;57:712-17.
11. Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol 2008;294:E148-E56.
12. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55:2256-64.
13. Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99-111.
14. Liu WH, Hei ZQ, Nie H, et al. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008;121:706-12.
15. Tang LQ, Lv F, Liu S, et al. Effect of berberine on expression of transforming growth factor-b1 and FN proteins in mesangial cells of diabetic rats with nephropathy. Chin J Chin Mater Med 2011;36: 3494-7.
16. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559-65.
17. Xie X, Chang XT, Chen L, et al. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling. Mol Cell Endocrinol 2013;381:56-65.
18. Domitrović R, Cvijanović O, Pernjak-Pugel E, et al. Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food Chem Toxicol 2013;62C: 397-406.
19. Liu S, Tang LQ, Chen LM. Study on extraction technology of berberine from Rhizoma coptidis by the method of orthogonal-test optimization. China Pharmacy 2004;15:18-20.
20. Zhang JT. Modern experimental methods in pharmacology. Beijing: Beijing Medical University; 1998:982.
21. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebocontrolled trial. Lancet 2010;375:2223-33.
22. Vladimirova-Kitova LG, Deneva TI. Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Clin Lab 2010; 56:291-302.
23. Xu XX, Zhang W, Zhang P, et al. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Phytomedicine 2013;20:820-7.
24. Itoh Y, Imamura S, Yamamoto K, et al. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate. J Endocrinol 2002;175:233-9.
25. Yang F, Tang LQ, Wang FL, et al. Study of the influential factor on the establishment of experimental diabetic nephropathy in rats. Anhui Med Pharm J 2011;16:735-8.
26. Danda RS, Habiba NM, Rincon-Choles H, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005; 68:2562-71.
27. Thompson J, Wilson P, Brandewie K, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol 2011;179:1179-87.
28. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59: 260-9.
29. Zhang Q, Xiao X, Feng K, et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid Based Complement Alternat Med 2011;2011.
30. Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008;70:357-77.
31. Purdy KE, Arendshorst WJ. EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 2000;279:F755-64.
32. Schweda F, Klar J, Narumiya S, et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 2004;287:F427-33.
33. Nagamatsu T, Imai H, Yokoi M, et al. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. J Pharmacol Sci 2006; 102:182-8.
34. Nagamatsu T, Imai H, Yokoi M, et al. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. J Pharmacol Sci 2006; 102:182-8.
35. Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 2006;290:F1534-42.
36. Yamamoto E, Izawa T, Juniantito V, et al. Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. Histol Histopathol 2010; 25:995-1007.
37. Liu Y, Rajagopal M, Lee K, et al. Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. Am J Physiol Renal Physiol 2012;303:F1425-34.
38. Wu J, Zhang Y, Frilot N, et al. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011;286:33954-62.